<DOC>
	<DOC>NCT01228513</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.</brief_summary>
	<brief_title>Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria Body surface area affected by atopic dermatitis at or less than 15% at start of treatment Pregnancy and breastfeeding Conditions that may pose a threat to the patient or effect the outcome of the study Widespread atopic dermatitis (AD) requiring systemic treatment Immunocompromized conditions At least 2 weeks after local AD treatment and treatment with systemic antibiotics At least 1 month after systemic AD treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>